



## Exercise of options

June 25, 2021

RNS Number : 1945D

Renalytix PLC

25 June 2021

**Renalytix plc**  
("Renalytix" or the "Company")

### **Exercise of options and total voting rights**

**NEW YORK, June 25, 2021** - [Renalytix plc](https://www.renalytix.com) (LSE: RENX) (NASDAQ: RNLX) announces that it has issued and allotted 150,000 ordinary shares of 0.25 pence each in the share capital of the Company ("Ordinary Shares") following an exercise of options on 24 June 2021. The exercise price was 121 pence per Ordinary Share.

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 150,000 new Ordinary Shares to trading on AIM will become effective on, or around, 1 July 2021 ("Admission").

### **Total voting rights**

Following Admission, the Company will have 72,197,286 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 72,197,286.

***For further information, please contact:***

**Renalytix AI plc**  
James McCullough, CEO

[www.renalytix.com](https://www.renalytix.com)  
**Via Walbrook PR**

**Stifel (Nominated Adviser, Joint Broker)**  
Alex Price / Nicholas Moore

**Tel: 020 7710 7600**

**Investec Bank plc (Joint Broker)**  
Gary Clarence / Daniel Adams

**Tel: 020 7597 4000**

**Walbrook PR Limited**  
Paul McManus / Lianne Cawthorne

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)  
Mob: 07980 541 893 / 07584 391 303

### **About Kidney Disease**

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.<sup>1</sup> Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

### **About KidneyIntelX**

KidneyIntelX, is a first-of-kind, bioprognostic<sup>TM</sup> platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

### **About Renalytix**

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit [www.kidneyintelx.com](http://www.kidneyintelx.com)). For more information, visit [www.renalytix.com](http://www.renalytix.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOESEUFFIEFSELM